All Stories

  1. The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis

    Article • PLoS Biology, September 2025, PLOS

    Dr. Ron Milo

  2. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2025, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo

  3. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

    Article • Pharmacological Reviews, November 2024, Elsevier

    Dr. Ron Milo

  4. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

    Article • Neurology and Therapy, July 2023, Springer Science + Business Media

    Dr. Ron Milo

  5. Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint

    Article • Journal of Neurology, July 2023, Springer Science + Business Media

    Dr. Ron Milo

  6. The consequences of switching from Gilenya® to generics for fingolimod

    Article • Multiple Sclerosis and Related Disorders, June 2023, Elsevier

    Dr. Ron Milo

  7. B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

    Article • Frontiers in Immunology, March 2023, Frontiers

    Dr. Ron Milo

  8. Is There Horizontal Transmission of Creutzfeldt-Jakob Disease?

    Article • Neuroepidemiology, January 2023, Karger Publishers

    Dr. Ron Milo

  9. Genetic Creutzfeldt‐Jakob disease in Turkish Jews—demographic and clinical features

    Article • Acta Neurologica Scandinavica, August 2022, Wiley

    Dr. Ron Milo

  10. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses

    Article • Frontiers in Immunology, April 2022, Frontiers

    Dr. Ron Milo

  11. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

    Article • Movement Disorders, September 2021, Wiley

    Dr. Ron Milo

  12. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals

    Article • Multiple Sclerosis and Related Disorders, May 2021, Elsevier

    Dr. Ron Milo

  13. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5

    Article • Nature Communications, March 2021, Springer Science + Business Media

    Dr. Ron Milo

  14. Association between cervical disc disease and lesions of multiple sclerosis

    Article • The Neuroradiology Journal, January 2021, SAGE Publications

    Dr. Ron Milo

  15. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis

    Article • Journal of Palliative Medicine, November 2020, Mary Ann Liebert Inc

    Dr. Ron Milo, Professor Ivan G. Milanov, Dr. Alessandra Solari

  16. Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2020, New England Journal of Medicine (NEJM/MMS)

    Dr Pedro Jesus Serrano-Castro, Dr. Ron Milo, Professor Tjalf Ziemssen

  17. EAN guideline on palliative care of people with severe, progressive multiple sclerosis

    Article • European Journal of Neurology, May 2020, Wiley

    Dr. Alessandra Solari, Dr. Ron Milo, Professor Ivan G. Milanov

  18. Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course

    Article • Journal of Neurology, May 2020, Springer Science + Business Media

    Dr. Ron Milo

  19. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis

    Article • European Journal of Neurology, February 2020, Wiley

    Dr. Ron Milo

  20. Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis

    Article • European Neurological Review, January 2020, Touch Digital Media, Ltd.

    Dr. Ron Milo

  21. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis

    Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

    Dr. Ron Milo

  22. Immunological Aspects of Approved MS Therapeutics

    Article • Frontiers in Immunology, July 2019, Frontiers

    Dr. Ron Milo

  23. B Cell-based Therapies for Multiple Sclerosis

    Article • June 2019, Royal Society of Chemistry

    Dr. Ron Milo

  24. Therapies for multiple sclerosis targeting B cells

    Article • Croatian Medical Journal, April 2019, Croatian Medical Journal

    Dr. Ron Milo

  25. A retrospective analysis of the development of seizure frequency in patients with seizures during a period of military conflict

    Article • Seizure, October 2018, Elsevier

    Dr. Ron Milo

  26. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis

    Article • Expert Review of Clinical Pharmacology, August 2017, Taylor & Francis

    Dr. Ron Milo

  27. Spotlight on daclizumab: its potential in the treatment of multiple sclerosis

    Article • Degenerative Neurological and Neuromuscular Disease, November 2016, Dove Medical Press

    Dr. Ron Milo

  28. Therapeutic strategies targeting B-cells in multiple sclerosis

    Article • Autoimmunity Reviews, July 2016, Elsevier

    Dr. Ron Milo

  29. Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs

    Article • Expert Opinion on Pharmacotherapy, January 2015, Informa Healthcare

    Dr. Ron Milo

  30. Revised diagnostic criteria of multiple sclerosis

    Article • Autoimmunity Reviews, April 2014, Elsevier

    Dr. Ron Milo

  31. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis

    Article • Therapeutic Advances in Neurological Disorders, September 2013, SAGE Publications

    Dr. Ron Milo

  32. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis

    Article • Archives of Neurology, October 2012, American Medical Association (AMA)

    Dr. Ron Milo, Prof Roy G Beran

  33. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2012, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo

  34. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

    Article • The Lancet Neurology, May 2012, Elsevier

    Dr. Ron Milo, Prof Roy G Beran

  35. Stroke in the Very Elderly: Characteristics and Outcome in Patients Aged =85 Years with a First-Ever Ischemic Stroke

    Article • Neuroepidemiology, January 2012, Karger Publishers

    Dr. Ron Milo

  36. The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors

    Article • Autoimmunity Reviews, June 2011, Elsevier

    Dr. Ron Milo

  37. Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review

    Article • Therapeutic Advances in Neurological Disorders, May 2011, SAGE Publications

    Dr. Ron Milo

  38. In Memoriam: Hillel S. Panitch, MD (1940-2010)

    Article • Archives of Neurology, May 2011, American Medical Association (AMA)

    Dr. Ron Milo

  39. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease

    Article • Journal of Neural Transmission, February 2011, Springer Science + Business Media

    Dr. Ron Milo

  40. Combination therapy in multiple sclerosis

    Article • Journal of Neuroimmunology, February 2011, Elsevier

    Dr. Ron Milo

  41. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

    Article • Annals of Neurology, January 2011, Wiley

    Dr. Ron Milo

  42. Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel

    Article • Journal of Neurology, September 2010, Springer Science + Business Media

    Dr. Ron Milo

  43. Translational Research in Neurology and Neuroscience 2010

    Article • Archives of Neurology, July 2010, American Medical Association (AMA)

    Dr. Ron Milo

  44. Multiple sclerosis: Geoepidemiology, genetics and the environment

    Article • Autoimmunity Reviews, March 2010, Elsevier

    Dr. Ron Milo

  45. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2010, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof Roy G Beran

  46. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke

    Article • Stroke, November 2009, Wolters Kluwer Health

    Dr. Ron Milo

  47. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

    Article • The Lancet Neurology, October 2009, Elsevier

    Dr. Ron Milo

  48. Local corticosteroid treatment for carpal tunnel syndrome: A 6-month clinical and electrophysiological follow-up study

    Article • Journal of Back and Musculoskeletal Rehabilitation, June 2009, IOS Press

    Dr. Ron Milo

  49. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial

    Article • The Lancet, December 2008, Elsevier

    Professor Malcolm R Macleod, Alba Piroli, Professor David Torgerson, Dr. Ron Milo, Prof. Endre Pal

  50. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PR...

    Article • The Lancet Neurology, October 2008, Elsevier

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, DMSci, Neurologist Helle K. Iversen

  51. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2008, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, DMSci, Neurologist Helle K. Iversen

  52. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2008, New England Journal of Medicine (NEJM/MMS)

    Dr. Ron Milo, Prof. Dr. Otto W. Witte, DMSci, Neurologist Helle K. Iversen

  53. Multiple Sclerosis

    Article • January 2008, Springer Science + Business Media

    Dr. Ron Milo

  54. The utility of the Visual Analogue Scale for the assessment of depressive mood in cognitively impaired patients

    Article • International Journal of Geriatric Psychiatry, July 2004, Wiley

    Prof ABRAHAM WEIZMAN, Dr. Ron Milo

  55. The Myelin-Associated Oligodendrocytic Basic Protein Region MOBP15–36 Encompasses the Immunodominant Major Encephalitogenic Epitope(s) for SJL/J Mice and Predicted Epitope(s) for Multiple Sclerosis-Associated HLA-DRB1*1501

    Article • The Journal of Immunology, July 2004, The American Association of Immunologists

    Dr. Ron Milo

  56. Neurological features of West Nile Virus infection during the 2000 outbreak in a regional hospital in Israel

    Article • Journal of the Neurological Sciences, August 2002, Elsevier

    Dr. Ron Milo

  57. Bilateral vestibular failure as a unique presenting sign in carcinomatous meningitis: case report

    Article • Journal of Neurology Neurosurgery & Psychiatry, May 2001, BMJ

    Dr. Ron Milo

  58. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases

    Article • Annals of the Rheumatic Diseases, January 2000, BMJ

    Dr. Ron Milo

  59. Glatiramer Acetate or Interferon-?? for Multiple Sclerosis?

    Article • CNS Drugs, January 1999, Springer Science + Business Media

    Dr. Ron Milo

  60. Effect of Propranolol and IFN-β on the Induction of MHC Class II Expression and Cytokine Production by IFN-γ in THP-1 Human Monocytic Cells

    Article • Immunopharmacology and Immunotoxicology, January 1998, Taylor & Francis

    Dr. Ron Milo

  61. Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ

    Article • European Journal of Pharmacology, January 1998, Elsevier

    Dr. Ron Milo

  62. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions

    Article • European Journal of Immunology, November 1997, Wiley

    Dr. Ron Milo

  63. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial

    Article • Neurology, December 1996, Wolters Kluwer Health

    Dr. Ron Milo

  64. Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein

    Article • Journal of Neuroimmunology, September 1995, Elsevier

    Dr. Ron Milo

  65. Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells

    Article • Journal of Neuroimmunology, August 1995, Elsevier

    Dr. Ron Milo

  66. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

    Article • Journal of Clinical Investigation, December 1993, American Society for Clinical Investigation

    Dr. Ron Milo

  67. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

    Article • Proceedings of the National Academy of Sciences, January 1992, Proceedings of the National Academy of Sciences

    Dr. Ron Milo

  68. Specific inhibition by the synthetic copolymer COP-1 of human T cell lines specific to myelin basic protein

    Article • Journal of Neuroimmunology, January 1991, Elsevier

    Dr. Ron Milo

  69. Tiapride as Treatment for Certain Patients with Idiopathic Torsion Dystonia

    Article • European Neurology, January 1991, Karger Publishers

    Dr. Ron Milo

  70. Delayed epidural hematoma a review

    Article • Acta Neurochirurgica, March 1987, Springer Science + Business Media

    Dr. Ron Milo

  71. Purulent meningitis due to Pseudomonas aeruginosa successfully treated with colistin and piperacillin

    Article • Journal of Infection, November 1985, Elsevier

    Dr. Ron Milo